Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 13
Submit an article Journal homepage
352
Views
9
CrossRef citations to date
0
Altmetric
Original Articles

High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis

Maria Queralt Salasa Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;c Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0003-4567-3682
ORCID Icon,
Shruti Prema Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Mats Rembergerd Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden
,
Wilson Lama Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Dennis Dong Hwan Kima Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Fotios Vasilios Michelisa Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Zeyad Al-Shaibania Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Armin Gerbitza Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Jeffrey Howard Liptona Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Auro Viswabandyaa Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Rajat Kumara Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
,
Deepali Kumare Transplant Infectious Diseases and Multi Organ Transplant Program, University Health Network, Toronto, ON, Canada
,
Jonas Mattssona Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
&
Arjun Datt Lawa Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada;b Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CanadaCorrespondence[email protected]
 show all
Pages 3198-3208 | Received 08 Feb 2020, Accepted 07 Jul 2020, Published online: 25 Jul 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

We explore risk factors and impacts of post-transplant EBV-Reactivation (EBV-R) and PTLD in 270 patients that underwent RIC alloHCT using ATG-PTCy and cyclosporine for GVHD prophylaxis. Twenty-five (12%) patients had probable (n = 7) or proven (n = 18) PTLD. Patients were managed with reduction of immunosuppression and 22 with weekly rituximab (375 mg/m2 IV). ORR was 84%; 8 (32%) recipients died, and one-year OS and NRM of patients with PTLD was 59.7% and 37%, respectively. One hundred seventy-two (63.7%) recipients had EBV-R. One-year OS and RFS of patients with EBV-R were 68.2% and 60.6%, and of EBV-Negative patients were 62.1% and 50.1%, respectively. High incidence but low mortality of EBV-R and PTLD was documented. EBV-R induced a protective effect on RFS in multivariable analysis (HR 0.91, p = .011). Therefore, EBV-R may have a protective effect on RFS in this setting. Further research is necessary to evaluate the interplay of EBV-R, immune reconstitution, and post-transplant outcomes.

Acknowledgments

The authors thank our patients and the nursing and support staff in the Hans Messner Allogeneic Blood and Marrow Transplant Program.

Author contributions

QS and AL designed the study, interpreted the data and wrote the manuscript. QS and SP collected the data. QS, MR did the statistical analysis. QS developed the research entirely during her stage at Princess Margaret Cancer Center. QS, SP, MR, WL, DHK, FM, ST, JL, AG, RK, JM, AV, JM, DK and AL provided valuable input into the study design and interpretation and reviewed the manuscript.

Disclosure statement

DK has received consulting fees from Atara Bio. The remaining authors declare no relevant conflicts of interest, financial or otherwise.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.